Capromorelin

Capromorelin has no FDA-approved human indication; all current use is off-label or sourced through compounding pharmacies. The human clinical record is minimal — one thin trial in actinic keratosis, with remaining evidence confined to animal models. There are no established dosing protocols or documented community use patterns to report, and the evidence base is genuinely thinner than the volume of surrounding interest suggests.

Capromorelin

Research Evidence

Evidence shape

Capromorelin's clinical record consists of one registered trial — Phase 1, in Actinic Keratosis — with a single linked publication and no results posted at scale. The remaining mapped research is preclinical: animal and mechanistic work that hasn't progressed to registered human trials. With nothing beyond Phase 1 and only one indication reaching any human-study threshold, the evidence base doesn't support conclusions about efficacy in any indication.

Depthhow much
0 registered trials
Breadthhow many areas
1 indication mapped
1 animal-only
Qualityhow rigorous
No completed trials
Breadth and depth8 rows captured
Human
direct clinical signal
0
Animal
translational support
6
In vitro
mechanistic support
2
HighMediumLow

Anecdotal efficacy

Price

No live vendor pricing captured for this peptide yet.

Dosing & Protocol

How Capromorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 3
Typical dose
No quantified dose captured for this tier.
Frequency
unspecified
Timing
unspecified
Route
oral
Cycle
unspecified

Anecdotal reports consistently highlight positive effects on appetite stimulation and increased food intake, with 3 out of 3 reports being positive. Specific dosing information is not consistently available in community discussions.

1 source

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Capromorelin, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.